LXRX
insider transactionsLEXICON PHARMACEUTICALS, INC. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 2 different insiders made open-market purchases in the last 365 days, totalling $2.7M.
Net shares · 365d
+2.1M
2.1M buy · 0 sell
Net value · 365d
$2.7M
$2.7M in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
8
2.1M buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
SVP, Discovery
—
65.6K sh
Own +100%
-
Exercise·M
SVP, Discovery
—
20.3K sh
Own New
-
Exercise·M
SVP, Discovery
—
14.0K sh
Own New
-
Exercise·M
SVP, Discovery
—
14.0K sh
Own +19%
-
Exercise·M
SVP, Discovery
—
20.3K sh
Own +23%
-
Other·F
SVP, Discovery
$35.8K
24.3K sh · $1.47
Own -14%
-
Exercise·M
SVP, Discovery
—
65.6K sh
Own +60%
-
Exercise·M
Coiante Scott M KEY
SVP, Chief Financial Officer
—
160.2K sh
Own +100%
-
Other·F
Coiante Scott M KEY
SVP, Chief Financial Officer
$80.7K
54.9K sh · $1.47
Own -34%
-
Exercise·M
Coiante Scott M KEY
SVP, Chief Financial Officer
—
160.2K sh
Own New
-
Exercise·M
SVP, IR and Corp Comm
—
128.2K sh
Own +100%
-
Exercise·M
SVP, IR and Corp Comm
—
24.7K sh
Own New
-
Exercise·M
SVP, IR and Corp Comm
—
24.7K sh
Own +158%
-
Exercise·M
SVP, IR and Corp Comm
—
128.2K sh
Own +318%
-
Other·F
SVP, IR and Corp Comm
$109.6K
74.6K sh · $1.47
Own -44%
-
Exercise·M
SVP, Partnerships & Corp Strat
—
67.1K sh
Own +100%
-
Exercise·M
SVP, Partnerships & Corp Strat
—
67.1K sh
Own New
-
Other·F
SVP, Partnerships & Corp Strat
$52.7K
35.8K sh · $1.47
Own -53%
-
Exercise·M
Exton Michael KEY
Chief Executive Officer
—
503.3K sh
Own +100%
-
Exercise·M
Exton Michael KEY
Chief Executive Officer
—
503.3K sh
Own New
-
Other·F
Exton Michael KEY
Chief Executive Officer
$301.1K
204.8K sh · $1.47
Own -41%
-
Exercise·M
SVP, Human Resources
—
27.7K sh
Own New
-
Exercise·M
SVP, Human Resources
—
144.4K sh
Own +100%
-
Exercise·M
SVP, Human Resources
—
52.3K sh
Own +5231600%
-
Other·F
SVP, Human Resources
$100.1K
68.1K sh · $1.47
Own -20%
-
Exercise·M
SVP, Human Resources
—
144.4K sh
Own +72%
-
Exercise·M
SVP, Human Resources
—
27.7K sh
Own +23%
-
Exercise·M
SVP, Human Resources
—
52.3K sh
Own +35%
-
Exercise·M
SVP, General Counsel & Secr.
—
33.5K sh
Own New
-
Exercise·M
SVP, General Counsel & Secr.
—
69.4K sh
Own +6938600%
-
Exercise·M
SVP, General Counsel & Secr.
—
170.2K sh
Own +100%
-
Exercise·M
SVP, General Counsel & Secr.
—
69.4K sh
Own +27%
-
Other·F
SVP, General Counsel & Secr.
$154.4K
105.0K sh · $1.47
Own -20%
-
Exercise·M
SVP, General Counsel & Secr.
—
33.5K sh
Own +10%
-
Exercise·M
SVP, General Counsel & Secr.
—
170.2K sh
Own +47%
-
Exercise·M
SVP, Chief Medical Officer
—
202.3K sh
Own +100%
-
Exercise·M
SVP, Chief Medical Officer
—
35.8K sh
Own New
-
Exercise·M
SVP, Chief Medical Officer
—
74.2K sh
Own +7422600%
-
Exercise·M
SVP, Chief Medical Officer
—
202.3K sh
Own +88%
-
Other·F
SVP, Chief Medical Officer
$160.4K
109.1K sh · $1.47
Own -25%
-
Exercise·M
SVP, Chief Medical Officer
—
74.2K sh
Own +48%
-
Exercise·M
SVP, Chief Medical Officer
—
35.8K sh
Own +30%
-
Buy·P
Director
$3.0K
2.0K sh · $1.49
Own +0%
-
Buy·P
Director
$147.0K
100.0K sh · $1.47
Own +6%
-
Buy·P
Director
$148.0K
100.0K sh · $1.48
Own +6%
-
Buy·P
Director
$72.0K
50.0K sh · $1.44
Own +3%
-
Buy·P
Director
$176.5K
133.7K sh · $1.32
Own +9%
-
Buy·P
Director
$100.7K
76.9K sh · $1.31
Own +5%
-
Grant·A
Director,TenPercentOwner
$2.7M
41.3K sh · $65.00
Own +11%
-
Buy·P
Director
$75.9K
58.0K sh · $1.31
Own +4%
-
Grant·A
SVP, Human Resources
$0
250.2K sh
Own New
-
Grant·A
SVP, Human Resources
$0
375.3K sh
Own New
-
Grant·A
Coiante Scott M KEY
SVP, Chief Financial Officer
$0
272.7K sh
Own New
-
Grant·A
Coiante Scott M KEY
SVP, Chief Financial Officer
$0
409.0K sh
Own New
-
Grant·A
Exton Michael KEY
Chief Executive Officer
$0
1.3M sh
Own New
-
Grant·A
Exton Michael KEY
Chief Executive Officer
$0
862.4K sh
Own New
-
Grant·A
SVP, Partnerships & Corp Strat
$0
193.7K sh
Own New
-
Grant·A
SVP, Partnerships & Corp Strat
$0
290.6K sh
Own New
-
Grant·A
SVP, Chief Medical Officer
$0
519.9K sh
Own New
-
Grant·A
SVP, Chief Medical Officer
$0
346.6K sh
Own New
-
Grant·A
SVP, Discovery
$0
238.4K sh
Own New
-
Grant·A
SVP, Discovery
$0
357.7K sh
Own New
-
Grant·A
SVP, IR and Corp Comm
$0
386.3K sh
Own New
-
Grant·A
SVP, IR and Corp Comm
$0
257.5K sh
Own New
-
Grant·A
SVP, General Counsel & Secr.
$0
299.7K sh
Own New
-
Grant·A
SVP, General Counsel & Secr.
$0
449.6K sh
Own New
-
Grant·A
Director,TenPercentOwner
$23.9M
367.1K sh · $65.00
Own New
-
Grant·A
Director,TenPercentOwner
$24.1M
18.6M sh · $1.30
Own +14%
-
Grant·A
Director,TenPercentOwner
$5.0M
3.8M sh · $1.30
Own +109%
-
Buy·P
Director,TenPercentOwner
$2.0M
1.5M sh · $1.30
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Feb 28, 2026 | Gopinathan Suma | Exercise M | 65.6K | — |
| Feb 28, 2026 | Gopinathan Suma | Exercise M | 20.3K | — |
| Feb 28, 2026 | Gopinathan Suma | Exercise M | 14.0K | — |
| Feb 28, 2026 | Gopinathan Suma | Exercise M | 14.0K | — |
| Feb 28, 2026 | Gopinathan Suma | Exercise M | 20.3K | — |
| Feb 28, 2026 | Gopinathan Suma | Other F | 24.3K | $35.8K |
| Feb 28, 2026 | Gopinathan Suma | Exercise M | 65.6K | — |
| Feb 28, 2026 | Coiante Scott M KEY | Exercise M | 160.2K | — |
| Feb 28, 2026 | Coiante Scott M KEY | Other F | 54.9K | $80.7K |
| Feb 28, 2026 | Coiante Scott M KEY | Exercise M | 160.2K | — |
| Feb 28, 2026 | DeFrancesco Lisa | Exercise M | 128.2K | — |
| Feb 28, 2026 | DeFrancesco Lisa | Exercise M | 24.7K | — |
| Feb 28, 2026 | DeFrancesco Lisa | Exercise M | 24.7K | — |
| Feb 28, 2026 | DeFrancesco Lisa | Exercise M | 128.2K | — |
| Feb 28, 2026 | DeFrancesco Lisa | Other F | 74.6K | $109.6K |
| Feb 28, 2026 | Martens Rachel Yap | Exercise M | 67.1K | — |
| Feb 28, 2026 | Martens Rachel Yap | Exercise M | 67.1K | — |
| Feb 28, 2026 | Martens Rachel Yap | Other F | 35.8K | $52.7K |
| Feb 28, 2026 | Exton Michael KEY | Exercise M | 503.3K | — |
| Feb 28, 2026 | Exton Michael KEY | Exercise M | 503.3K | — |
| Feb 28, 2026 | Exton Michael KEY | Other F | 204.8K | $301.1K |
| Feb 28, 2026 | McDermott Wendy | Exercise M | 27.7K | — |
| Feb 28, 2026 | McDermott Wendy | Exercise M | 144.4K | — |
| Feb 28, 2026 | McDermott Wendy | Exercise M | 52.3K | — |
| Feb 28, 2026 | McDermott Wendy | Other F | 68.1K | $100.1K |
| Feb 28, 2026 | McDermott Wendy | Exercise M | 144.4K | — |
| Feb 28, 2026 | McDermott Wendy | Exercise M | 27.7K | — |
| Feb 28, 2026 | McDermott Wendy | Exercise M | 52.3K | — |
| Feb 28, 2026 | Crum Brian T | Exercise M | 33.5K | — |
| Feb 28, 2026 | Crum Brian T | Exercise M | 69.4K | — |
| Feb 28, 2026 | Crum Brian T | Exercise M | 170.2K | — |
| Feb 28, 2026 | Crum Brian T | Exercise M | 69.4K | — |
| Feb 28, 2026 | Crum Brian T | Other F | 105.0K | $154.4K |
| Feb 28, 2026 | Crum Brian T | Exercise M | 33.5K | — |
| Feb 28, 2026 | Crum Brian T | Exercise M | 170.2K | — |
| Feb 28, 2026 | Granowitz Craig B | Exercise M | 202.3K | — |
| Feb 28, 2026 | Granowitz Craig B | Exercise M | 35.8K | — |
| Feb 28, 2026 | Granowitz Craig B | Exercise M | 74.2K | — |
| Feb 28, 2026 | Granowitz Craig B | Exercise M | 202.3K | — |
| Feb 28, 2026 | Granowitz Craig B | Other F | 109.1K | $160.4K |
| Feb 28, 2026 | Granowitz Craig B | Exercise M | 74.2K | — |
| Feb 28, 2026 | Granowitz Craig B | Exercise M | 35.8K | — |
| Feb 25, 2026 | DEBBANE RAYMOND | Buy P | 2.0K | $3.0K |
| Feb 23, 2026 | DEBBANE RAYMOND | Buy P | 100.0K | $147.0K |
| Feb 20, 2026 | DEBBANE RAYMOND | Buy P | 100.0K | $148.0K |
| Feb 19, 2026 | DEBBANE RAYMOND | Buy P | 50.0K | $72.0K |
| Feb 18, 2026 | DEBBANE RAYMOND | Buy P | 133.7K | $176.5K |
| Feb 17, 2026 | DEBBANE RAYMOND | Buy P | 76.9K | $100.7K |
| Feb 17, 2026 | Artal International S.C.A. | Grant A | 41.3K | $2.7M |
| Feb 13, 2026 | DEBBANE RAYMOND | Buy P | 58.0K | $75.9K |
| Feb 12, 2026 | McDermott Wendy | Grant A | 250.2K | $0 |
| Feb 12, 2026 | McDermott Wendy | Grant A | 375.3K | $0 |
| Feb 12, 2026 | Coiante Scott M KEY | Grant A | 272.7K | $0 |
| Feb 12, 2026 | Coiante Scott M KEY | Grant A | 409.0K | $0 |
| Feb 12, 2026 | Exton Michael KEY | Grant A | 1.3M | $0 |
| Feb 12, 2026 | Exton Michael KEY | Grant A | 862.4K | $0 |
| Feb 12, 2026 | Martens Rachel Yap | Grant A | 193.7K | $0 |
| Feb 12, 2026 | Martens Rachel Yap | Grant A | 290.6K | $0 |
| Feb 12, 2026 | Granowitz Craig B | Grant A | 519.9K | $0 |
| Feb 12, 2026 | Granowitz Craig B | Grant A | 346.6K | $0 |
| Feb 12, 2026 | Gopinathan Suma | Grant A | 238.4K | $0 |
| Feb 12, 2026 | Gopinathan Suma | Grant A | 357.7K | $0 |
| Feb 12, 2026 | DeFrancesco Lisa | Grant A | 386.3K | $0 |
| Feb 12, 2026 | DeFrancesco Lisa | Grant A | 257.5K | $0 |
| Feb 12, 2026 | Crum Brian T | Grant A | 299.7K | $0 |
| Feb 12, 2026 | Crum Brian T | Grant A | 449.6K | $0 |
| Feb 2, 2026 | Artal Group S.A. | Grant A | 367.1K | $23.9M |
| Feb 2, 2026 | Artal Group S.A. | Grant A | 18.6M | $24.1M |
| Feb 2, 2026 | Artal Group S.A. | Grant A | 3.8M | $5.0M |
| Feb 2, 2026 | Artal Group S.A. | Buy P | 1.5M | $2.0M |
About LXRX insider trading
This page tracks insider transactions for LEXICON PHARMACEUTICALS, INC. (LXRX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.